Bionomics Investor Presentation Deck
Acute Anxiety in SAD Represents a Significant Unmet Need
Social Anxiety Disorder (SAD), or Social Phobia, is a
significant and persistent fear of social and
performance-related situations
iso
●
Targeting a Large Segment of the Anxiety Market
●
●
Includes anxiety from everyday social situations as
well as "Fear of Public Speaking"
A disorder that substantially impacts many people's
daily lives
Amongst the largest mental health conditions with lifetime
prevalence affecting >31M Americans
No FDA-approved fast-acting medications for as-needed
treatment
Bionomics
Medications with the right pharmacokinetic profile and a
novel mechanism are needed
~31M
12.1% of adults
at some point
in their lives
~18M
7.1%
prevalence
in adults
Unmet medical need to large patient population
Advancement in care
No FDA-approved fast-acting competition
Ability to potentially achieve large market share
Sources:
US Census Bureau. https://www.census.gov/library/stories/2021/08/united-states-adult-population-grew-faster-than-nations-total-population-from-2010-to-2020.html
NIMH. 'Social Anxiety Disorder' data from 2017 National Comorbidity Survey (NCS). https://www.nimh.nih.gov/health/statistics/social-anxiety-disorder.shtml
Anxiety and Depression Association of America (ADAA). 'Social Anxiety Disorder - Understand the Facts' https://adaa.org/understanding-anxiety/social-anxiety-disorder
~7M
36% of adults
> 10 years SAD
symptoms
Opportunity
for BNC210
8View entire presentation